All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2006-006886-18 | Efficacy and Safety of Vivitrol® in Adults Completing Inpatient Treatment for Alcohol Dependence | 2011-01-04 | due-trials |
Reported results | 2012-003445-15 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects with Acute Exacerbation of Schizophrenia | 2014-03-11 | due-trials |
Reported results | 2012-003996-20 | A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects with Stable Schizophrenia | 2015-04-28 | due-trials |
Reported results | 2013-002193-45 | A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALK 3831, in Adults with Schizophrenia Treated with Olanzapine Randomizovaná, multice... | 2015-03-09 | due-trials |
Reported results | 2014-000379-14 | A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-5 Study) | 2016-09-27 | due-trials |
Reported results | 2014-000380-41 | A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant ... | 2017-11-20 | due-trials |
Reported results | 2014-000399-25 | A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study) | 2015-12-23 | due-trials |
Reported results | 2014-001211-39 | A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder | 2017-02-01 | due-trials |
Reported results | 2015-003373-15 | A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects with Acute Exacerbation of Schizophrenia | 2017-06-07 | due-trials |
Reported results | 2015-003880-13 | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | 2018-06-18 | due-trials |
Reported results | 2015-005160-41 | A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis | 2021-11-11 | due-trials |
Listed as ongoing, but also has a completion date and reported results | 2017-000497-11 | A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | 2021-12-01 | bad-data |
Listed as ongoing, but also has a completion date | 2017-000918-36 | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder | 2023-09-06 | bad-data |
Reported results | 2017-001294-16 | A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate | 2019-06-27 | due-trials |
Exempt | 2019-001998-90 | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors- ARTISTRY-1 | not-yet-due | |
Exempt | 2019-002013-20 | A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2) | 2023-03-01 | not-yet-due |
Ongoing | 2021-001557-31 | A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With ... | not-yet-due | |
Ongoing | 2021-002326-24 | A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovar... | not-yet-due | |
Exempt | 2022-003662-21 | Clinical and Immunologic Activity of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor P... | not-yet-due |